The osteopontin-c splice junction is important for anchorage-independent growth

Molecular Carcinogenesis

Volumn 53, Issue 6, 2014, Pages 480-487

  Shen, Hui ^a   Weber, Georg F ^a,b  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b MetaMol Theranostics   (United States)

Author keywords

Anchorage independence; Breast cancer; Metastasis; Osteopontin

Indexed keywords

ANTIBODY; OSTEOPONTIN; OSTEOPONTIN C; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH RATE; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; STABLE TRANSFECTION;

ANCHORAGE-INDEPENDENCE; BREAST CANCER; METASTASIS; OSTEOPONTIN;

ALTERNATIVE SPLICING; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OSTEOPONTIN; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ISOFORMS; TRANSFECTION;

EID: 84899954407     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21997     Document Type: Article

References (21)

1. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103:861-869.
2. Weber GF, Lett GS, Haubein NC. Meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep 2011; 25:433-441.
3. Mirza M, Shaughnessy E, Hurley JK, et al. OPN-c is a highly selective marker for breast cancer. Int J Cancer 2008; 122:889-897.
4. Patani N, Jiang W, Mokbel K. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer 2008; 122:2646.
5. Sullivan J, Blair L, Alnajar A, et al. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009; 146:232-240.
6. Tilli TM, Franco VF, Robbs BK, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011; 9:280-293.
7. He B, Mirza M, Weber GF. An OPN splice variant induces anchorage independence in human breast cancer. Oncogene 2006; 25:2192-2202.
8. Zhang G, He B, Weber GF. Growth factor signaling induces metastasis genes in transformed cells. A molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 2003; 23:6507-6519.
9. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60:2764-2769.
10. Sullivan J, Blair L, Alnajar A, et al. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol 2011; 26:893-904.
11. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012; 72:1688-1699.
12. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004; 21:515-523.
13. Sørensen ES, Højrup P, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 1995; 4:2040-2049.
14. Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 1990; 46:133-137.
15. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9:1291-1299.
16. Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun 1988; 157:166-173.
17. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 2005; 390:285-292.
18. Miyauchi A, Alvarez J, Greenfield EM, et al. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991; 266:20369-20374.
19. Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 1998; 111:1165-1174.
20. 1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999; 274:36328-36334.
21. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271:509-512. Erratum: Science 1998; 282: 243.